Is There a Generic for Bondlido?

No. The Orange Book lists no active FDA-approved generic (ANDA) for Bondlido (lidocaine). The Orange Book shows its last listed patent expires November 10, 2028 and its last listed exclusivity ends September 24, 2028.

Run it in Rivvi

Map Bondlido and your other top fills to their generics

Every strength in RxNorm, with brands that have no generic flagged.

Build the map

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Bondlido products in the Orange Book

Bondlido products and approved generics
Form and route	Strength	Brand status	Brand TE	Active generics	Generic TE codes
system, topical	10%	Marketed (Rx)	None	0	None

NDA 215029, held by MEDRX USA INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.

Bondlido patents

Patents listed for Bondlido
Patent	Expires	Covers	Use code	NDA
8722065	November 10, 2028	Drug product	None	215029

Bondlido exclusivity

Exclusivity listed for Bondlido
Code	Meaning	Expires	NDA
NP	New product	September 24, 2028	215029

Bondlido NDC codes

Questions

Is there a generic for Bondlido?

No. The Orange Book lists no active FDA-approved generic (ANDA) for Bondlido (lidocaine). The Orange Book shows its last listed patent expires November 10, 2028 and its last listed exclusivity ends September 24, 2028.

What is the generic name for Bondlido?

The active ingredient in Bondlido is lidocaine, per the FDA Orange Book.

When does the Bondlido patent expire?

The last patent listed for Bondlido in the Orange Book expires November 10, 2028. A listed patent expiry date is not a generic launch date.

What does a therapeutic equivalence code mean?

In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.